Michael Korn

551 total citations
18 papers, 256 citations indexed

About

Michael Korn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Korn has authored 18 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Michael Korn's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Metastasis and carcinoma case studies (2 papers). Michael Korn is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Metastasis and carcinoma case studies (2 papers). Michael Korn collaborates with scholars based in United States, Germany and United Kingdom. Michael Korn's co-authors include S. Seeber, U. Klaassen, Wilfried Eberhardt, Dirk Strumberg, H. Wilke, Alan P. Venook, Amy Ko, A. Harstrick, Emily K. Bergsland and Thomas Weber and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Annals of Oncology.

In The Last Decade

Michael Korn

18 papers receiving 248 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Korn United States 10 166 62 57 55 52 18 256
Alberto Romero Argentina 10 228 1.4× 92 1.5× 39 0.7× 59 1.1× 71 1.4× 19 352
Seshadri Thirumala United States 9 79 0.5× 76 1.2× 83 1.5× 21 0.4× 33 0.6× 21 280
Marek Kania United States 8 119 0.7× 66 1.1× 52 0.9× 27 0.5× 56 1.1× 26 196
T. Giannakakis Greece 13 367 2.2× 90 1.5× 79 1.4× 60 1.1× 68 1.3× 24 457
Mary McCauley United States 7 129 0.8× 58 0.9× 60 1.1× 59 1.1× 14 0.3× 13 306
Isabel Alvarado Mexico 11 262 1.6× 110 1.8× 65 1.1× 60 1.1× 196 3.8× 20 457
Han Xiao United States 10 124 0.7× 165 2.7× 65 1.1× 22 0.4× 106 2.0× 34 332
М. Yu. Fedyanin Russia 8 198 1.2× 104 1.7× 41 0.7× 24 0.4× 83 1.6× 107 308
Mara A. Cafferata Italy 10 195 1.2× 243 3.9× 68 1.2× 51 0.9× 68 1.3× 23 399
Jess Frank United States 10 153 0.9× 183 3.0× 38 0.7× 51 0.9× 51 1.0× 13 323

Countries citing papers authored by Michael Korn

Since Specialization
Citations

This map shows the geographic impact of Michael Korn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Korn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Korn more than expected).

Fields of papers citing papers by Michael Korn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Korn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Korn. The network helps show where Michael Korn may publish in the future.

Co-authorship network of co-authors of Michael Korn

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Korn. A scholar is included among the top collaborators of Michael Korn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Korn. Michael Korn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Aicher, Wilhelm K., Michael Korn, Joerg Hennenlotter, et al.. (2021). Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. BMC Urology. 21(1). 60–60. 12 indexed citations
2.
Dietrich, Marion, et al.. (2020). 379 Frequency and molecular associations of KRAS mutations in gynecologic malignancies. A158.2–A159. 1 indexed citations
3.
Magee, Daniel, Zoran Gatalica, Adam Stark, et al.. (2018). Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.. Journal of Clinical Oncology. 36(15_suppl). 12067–12067. 2 indexed citations
4.
5.
Tannir, Nizar M., Aung Naing, Jeffrey R. Infante, et al.. (2018). Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology. 36(15_suppl). 4509–4509. 9 indexed citations
6.
Chien, A. Jo, Thach‐Giao Truong, Michelle Melisko, et al.. (2013). Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.. Journal of Clinical Oncology. 31(15_suppl). 2605–2605. 3 indexed citations
7.
Shih, Kent C., Johanna C. Bendell, Suzanne F. Jones, et al.. (2012). Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.. Journal of Clinical Oncology. 30(15_suppl). 3006–3006. 14 indexed citations
8.
Venook, Alan P., Amy Ko, Margaret A. Tempero, et al.. (2008). Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. Journal of Clinical Oncology. 26(15_suppl). 15545–15545. 42 indexed citations
9.
Yount, Garret, et al.. (2001). Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene. 20(22). 2826–2835. 24 indexed citations
10.
11.
Klaassen, U., H. Wilke, Carolin Müller, et al.. (1997). Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.. PubMed. 11(4 Suppl 3). 38–40. 2 indexed citations
12.
Stahl, M., U. Vanhoefer, U. Fink, et al.. (1996). Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. Oncology Research and Treatment. 19(5). 416–418. 6 indexed citations
13.
Harstrick, A., Hans‐Joachim Wilke, Wilfried Eberhardt, et al.. (1996). A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer. Oncology Research and Treatment. 19(2). 153–156. 20 indexed citations
14.
Klaassen, U., H. Wilke, Dirk Strumberg, et al.. (1996). Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. European Journal of Cancer. 32(3). 547–549. 60 indexed citations
15.
Wilke, H., Michael Korn, U. Fink, et al.. (1996). Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.. PubMed. 6(3). 123–6. 12 indexed citations
16.
Klaassen, U., Hans‐Joachim Wilke, Dirk Strumberg, et al.. (1995). 360 Phase I/II study with paclitaxel in combination with weekly high dose 5-FU/Folinic acid in the treatment of metastatic breast cancer. European Journal of Cancer. 31. S78–S78. 6 indexed citations
17.
Dische, Stanley, D. Fermont, Robert U. Ashford, et al.. (1990). Who gets radiotherapy?. PubMed. 22(2). 78–83. 22 indexed citations
18.
Korn, Michael. (1990). Emotionally and practically supporting those attending a radiotherapy department and radiographers working with them.. PubMed. 56(640). 24–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberto Romero Breakdown of academic impact, for papers by Seshadri Thirumala Breakdown of academic impact, for papers by Marek Kania Breakdown of academic impact, for papers by T. Giannakakis Breakdown of academic impact, for papers by Mary McCauley Breakdown of academic impact, for papers by Isabel Alvarado Breakdown of academic impact, for papers by Han Xiao Breakdown of academic impact, for papers by М. Yu. Fedyanin Breakdown of academic impact, for papers by Mara A. Cafferata Breakdown of academic impact, for papers by Jess Frank
Rankless by CCL
2026